NCT06932198View on ClinicalTrials.gov

Bioequivalence Study to Compare Selexipag 400mcg Film Coated Tablets (400 mcg Selexipag) Versus Uptravi® 400mcg Film Coated Tablets (400 mcg Selexipag)

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

January 9, 2025

Primary Completion Date

March 3, 2025

Study Completion Date

March 25, 2025

Conditions
Pulmonary Arterial Hypertension (PAH)
Interventions
DRUG

Selexipag Film Coated Tablets

1 tablet

DRUG

Uptravi® Film Coated Tablets

1 tablet

Trial Locations (1)

11190

ACDIMA Center, Amman

All Listed Sponsors
lead

Humanis Saglık Anonim Sirketi

INDUSTRY

NCT06932198 - Bioequivalence Study to Compare Selexipag 400mcg Film Coated Tablets (400 mcg Selexipag) Versus Uptravi® 400mcg Film Coated Tablets (400 mcg Selexipag) | Biotech Hunter | Biotech Hunter